COVID-19 vaccines are estimated to have prevanented 20 million deaths worldwide in the first year of the vaccine programme, modelling study finds

  • First modelling study to quantify the impact of COVID-19 vaccines on a global scale estimates that 19.8 million out of a potential 31.4 million deaths were prevented in the first year after vaccines were introduced (8 December 2020 – 8 December 2021).
  • High and upper-middle income countries accounted for the greatest number of prevented deaths (12.2 million/ 19.8 million), highlighting inequalities in access to vaccines around the world.
  • A further 599,300 deaths could have been averted if the World Health Organisation’s target of vaccinating 40% of the population in every country by the end of 2021 had been met.
  • Study is based on data from 185 countries and territories and is the first to assess deaths averted directly and indirectly as a result of COVID-19 vaccination, using COVID-19 death records and total excess deaths from each country (or estimates where official data was not available). 


COVID-19 vaccines reduced the potential global death toll during the pandemic by more than half in the year following their implementation, a mathematical modelling study published today in The Lancet Infectious Diseases estimates.

In the first year of the vaccination programme, 19.8 million out of a potential 31.4 million COVID-19 deaths were prevented worldwide according to estimates based on excess deaths from 185 countries and territories.

The study estimates a further 599,300 lives could have been saved if the World Health Organisation’s target of vaccinating 40% of the population in each country with two or more doses by the end of 2021 had been met.

Dr Oliver Watson, lead author of the study, from Imperial College London, said: “Our findings offer the most complete assessment to date of the remarkable global impact that vaccination has had on the COVID-19 pandemic. Of the almost 20 million deaths estimated to have been prevented in the first year after vaccines were introduced, almost 7.5 million deaths were prevented in countries covered by the COVID-19 Vaccine Access initiative (COVAX). This initiative was set up because it was clear early on that global vaccine equity would be the only way out of the pandemic. Our findings show that millions of lives have likely been saved by making vaccines available to people everywhere, regardless of their wealth. However, more could have been done. If the targets set out by the WHO had been achieved, we estimate that roughly 1 in 5 of the estimated lives lost due to COVID-19 in low-income countries could have been prevented. ”[1]

Since the first COVID-19 vaccine was administered outside of a clinical trial setting on 8 December 2020, almost two thirds of the world’s population has received at least one dose of a COVID-19 vaccine (66%) [2]. The COVID-19 Vaccine Access initiative (COVAX) has facilitated access to affordable vaccines for lower income countries to try to reduce inequalities, with an initial target of giving two vaccine doses to 20% of the population in countries covered by the commitment by the end of 2021. The World Health Organisation expanded this target by setting a global strategy to fully vaccinate 70% of the world’s population by mid-2022, with an interim target of vaccinating 40% of the population of all countries by the end of 2021.

Despite the incredible speed of the vaccine roll-out worldwide, more than 3.5 million COVID-19 deaths have been reported since the first vaccine was administered in December 2020.

Several studies have sought to estimate the impact of vaccination on the course of the pandemic. These studies have focused on specific regions, such as individual countries, states, or cities. The latest study is the first to estimate the impact of COVID-19 vaccinations on a global scale and the first to assess the number of deaths averted both directly and indirectly.

Mr Gregory Barnsley, co-first author of the study, from Imperial College London, said: “Quantifying the impact that vaccination has made globally is challenging because access to vaccines varies between countries, as does our understanding of which COVID-19 variants have been circulating, with very limited genetic sequence data available for many countries. It is also not possible to directly measure how many deaths would have occurred without vaccinations. Mathematical modelling offers a useful tool for assessing alternative scenarios, which we can’t directly observe in real life.” [1]

To estimate the impact of global vaccination programmes, the researchers used an established model of COVID-19 transmission using country-level data for officially recorded COVID-19 deaths occurring between 8 December 2020 and 8 December 2021. To account for under-reporting of deaths in countries with weaker surveillance systems, they carried out a separate analysis based on the number of excess deaths recorded above those that would have been expected during the same time period. Where official data was not available, the team used estimates of all-cause excess mortality. These analyses were compared with an alternative hypothetical scenario in which no vaccines were delivered.

The model accounted for variation in vaccination rates between countries, as well as differences in vaccine efficacy in each country based on the vaccine types known to have been predominately used in those areas. Notably, China was not included in the analysis owing to its large population and very strict lockdown measures, which would have skewed the findings.

The team found that, based on officially recorded COVID-19 deaths, an estimated 18.1 million deaths would have occurred during the study period if vaccinations had not been implemented. Of these, the model estimates that vaccination has prevented 14.4 million deaths, representing a global reduction of 79%. These findings do not account for under-reporting of COVID-19 deaths, which is common in lower income countries. The team did a further analysis based on total excess deaths during the same time period to account for this. They found that COVID-19 vaccination prevented an estimated 19.8 million deaths out of a total of 31.4 million potential deaths that would have occurred without vaccination, a reduction of 63%.

More than three quarters (79%, 15.5 million/ 19.8 million) of deaths averted were due to the direct protection against severe symptoms provided by vaccination, leading to lower mortality rates. The remaining 4.3 million averted deaths were estimated to have been prevented by indirect protection from reduced transmission of the virus in the population and reduced burden on healthcare systems, thereby improving access to medical care for those most in need.

Vaccine impact changed over time and in different areas of the world as the pandemic progressed, the study found. In the first half of 2021, the greatest number of deaths averted by vaccination was seen in lower middle-income countries, resulting from the significant epidemic wave in India as the Delta variant emerged. This subsequently shifted to the greatest impact being concentrated in higher income countries in the second half of 2021, as restrictions on travel and social mixing were eased in some areas leading to greater virus transmission.

Overall, the number of estimated deaths prevented per person was greatest in high income countries, reflecting the earlier and wider roll out of vaccination campaigns in these areas (66 deaths prevented per 10,000 people in high-income countries vs 2.711 deaths prevented per 10,000 people in low-income countries). High and upper-middle income countries accounted for the greatest number of deaths averted (12.2 million/ 19.8 million), highlighting inequalities in access to vaccines around the world.

For the 83 countries included in the analysis that are covered by the COVAX commitment to affordable vaccines, an estimated 7.4 million deaths were averted out of a potential 17.9 million (41%). However, failure to meet the COVAX target of fully vaccinating 20% of the population in some countries is estimated to have resulted in an additional 156,900 deaths. Though this figure represents a small proportion of the total global deaths, these preventable deaths were concentrated in 31 African nations, where 132,700 deaths could have been averted if the target had been met.

Similarly, the shortfall in the WHO target of fully vaccinating 40% of the population of each country by the end of 2021 is estimated to have contributed to an additional 599,300 deaths worldwide that could have been prevented. Lower-middle income countries accounted for the majority of these deaths (347,500/599,300 [59.7%]). Regionally, most of these deaths were focused in the Africa and Eastern Mediterranean regions (348,900/599,300 [58.2%] and 126,800/599,300 [21.2%] respectively). If the 40% target had been met in all low-income countries, the number of deaths averted by vaccination in these areas would have more than doubled (200,000 additional deaths prevented on top of the 180,300 deaths estimated to have been averted under current vaccination rates).

Prof Azra Ghani, Chair in Infectious Disease Epidemiology at Imperial College London: “Our study demonstrates the enormous benefit that vaccines had in reducing deaths from COVID-19 globally. Whilst the intense focus on the pandemic has now shifted, it is important that we ensure the most vulnerable people in all parts of the world are protected from ongoing circulation of COVID-19 and from the other major diseases that continue to disproportionately affect the poorest. Ensuring fair access to vaccines is crucial, but requires more than just donating vaccines. Improvements in vaccine distribution and infrastructure, as well as coordinated efforts to combat vaccine misinformation and improve vaccine demand, are needed. Only then can we ensure that everyone has the opportunity to benefit from these life-saving technologies.” [1]

The authors note several limitations to their findings. Notably, their model is based on a number of necessary assumptions, including the precise proportions of which vaccine types have been delivered, how they were delivered and the precise timing of when new virus variants arrived in each country. They also assumed that the relationship between age and the proportion of COVID-19 deaths occurring among infected individuals is the same for each country. More broadly, the findings from the study should be considered in the context of uncertainty in calculating the true death toll of the pandemic owing to the difference in country-level reporting of COVID-19 mortality.

Writing in a linked Comment, Professor Alison Galvani, who was not involved in the study, from Yale University School of Public Health, USA, said: „The saving of more than 19 million lives by the unprecedented rapidity of development and roll-out of COVID-19 vaccines is an extraordinary global health feat. Nonetheless, millions of additional lives could be saved by more equitable distribution of vaccines.”

She added: „High coverage in an individual country not only benefits that country but contributes to worldwide reduction in transmission and emergence of novel variants. An enduring collective response is both pragmatic and ethically imperative.“



The study was carried out by researchers at the Medical Research Council Centre for Global Infectious Disease Analysis at Imperial College London, UK. It was funded by a Schmidt Science Fellowship in partnership with the Rhodes Trust, World Health Organisation, UK Medical Research Council, Gavi, Bill and Melinda Gates Foundation, National Institute for Health Research and Community Jameel.

[1] Quote direct from author and cannot be found in the text of the Article.
[2] Our World in Data: (accessed 29 May 2022)]

The labels have been added to this press release as part of a project run by the Academy of Medical Sciences seeking to improve the communication of evidence. For more information, please see: if you have any questions or feedback, please contact The Lancet press office


The Lancet Infectious Diseases



Method of Research

Computational simulation/modeling

Subject of Research

Not applicable

Article Title

Global impact of the first year of COVID-19 vaccination: a mathematical modelling study

Article Publication Date


COI Statement

ACG has received personal consultancy fees from HSBC, GlaxoSmithKline, and WHO related to COVID-19 epidemiology and from The Global Fund to Fight AIDS, Tuberculosis and Malaria for work unrelated to COVID-19. ACG is a non-remunerated member of scientific advisory boards for Moderna and the Coalition for Epidemic Preparedness. ABH and PW have received personal consultancy related to COVID-19 work from WHO. All other authors declare no competing interests.



The Lancet, 23.06.2022 (tB).



Schlagwörter: , ,


IU School of Medicine researchers develop blood test for anxiety
COVID-19 pandemic increased rates and severity of depression, whether people…
COVID-19: Bacterial co-infection is a major risk factor for death,…
Regenstrief-led study shows enhanced spiritual care improves well-being of ICU…
Hidden bacteria presents a substantial risk of antimicrobial resistance in…


Sorgen und Versorgen – Schmerzmedizin konkret: „Sorge als identitätsstiftendes Element…
Problem Schmerzmittelkonsum
Post-Covid und Muskelschmerz
Kopfschmerz bei Übergebrauch von Schmerz- oder Migränemitteln
Wenn die Schmerzbehandlung zur Dienstleistung wird


Diabetes mellitus: eine der großen Volkskrankheiten im Blickpunkt der Schmerzmedizin
Suliqua®: Einfacher hin zu einer guten glykämischen Kontrolle
Menschen mit Diabetes während der Corona-Pandemie unterversorgt? Studie zeigt auffällige…
Suliqua® zur Therapieoptimierung bei unzureichender BOT
„Wissen was bei Diabetes zählt: Gesünder unter 7 PLUS“ gibt…


Interdisziplinäre Diagnostik und Behandlung von Orthorexie
Warum hungrige Mäuse Sex dem Fressen vorziehen
Gesunde Ernährung: „Nicht das Salz und nicht das Fett verteufeln“
Mangelernährung gefährdet den Behandlungserfolg — DGEM: Ernährungsscreening sollte zur klinischen…
Wie eine Diät die Darmflora beeinflusst: Krankenhauskeim spielt wichtige Rolle…


Zanubrutinib bei chronischer lymphatischer Leukämie: Zusatznutzen für bestimmte Betroffene
Eileiter-Entfernung als Vorbeugung gegen Eierstockkrebs akzeptiert
Antibiotika als Störfaktor bei CAR-T-Zell-Therapie
Bauchspeicheldrüsenkrebs: Spezielle Diät kann Erfolg der Chemotherapie beeinflussen
Meilenstein in der Krebsversorgung am UKW: 100ste Patient erhält CAR-T-Zelltherapie


Neuer Biomarker für Verlauf von Multipler Sklerose
Multiple Sklerose: Analysen aus Münster erhärten Verdacht gegen das Epstein-Barr-Virus
Aktuelle Daten zu Novartis Ofatumumab und Siponimod bestätigen Vorteil des…
Multiple Sklerose durch das Epstein-Barr-Virus – kommt die MS-Impfung?
Neuer Therapieansatz für Multiple Sklerose und Alzheimer


Cochrane Review: Bewegung hilft, die Schwere von Bewegungssymptomen bei Parkinson…
Technische Innovationen für eine maßgeschneiderte Parkinson-Diagnostik und Therapie
Biomarker und Gene: neue Chancen und Herausforderungen für die Parkinson-Diagnose…
Heilung in Sicht? Fortschritte auf dem Weg zur kausalen Therapie
Verändertes Darmmikrobiom bei Parkinson-Erkrankten mit Blinddarmoperation